Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvogen and Reddy’s Cleared Over US Rivals To Suboxone

Executive Summary

Alvogen and Dr Reddy’s do not infringe key patents protecting Indivior’s Suboxone Film, the US Court of Appeals has confirmed. But Teva continues to fall foul of a production patent running until 2024.

You may also be interested in...



Dr Reddy’s Gets $72m Payout From Suboxone Settlement

Dr Reddy’s is in line for a $72m payout after settling US patent and antitrust litigation over Suboxone with Indivior.

Indivior Pays Out Over Blocking US Suboxone Rivals

Indivior has agreed to pay $10m to settle antitrust charges by the US Federal Trade Commission over its Suboxone brand.

Reddy’s Will Look For Acquisitions Under New CEO Israeli

With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel